Product Information
MOUNJARO 12.5 MG/0.5 ML PEN is a brand product labeled by Eli Lilly and Company, priced at $538.5252 per ML under NDC 00002146080. Its NADAC has been published 202 times since Nov 23, 2022.
FDA first approved this application on May 13, 2022.
Strength
12.5 mg/.5mL
Manufacturer
Eli Lilly and CompanyNDC
00002146080
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
TIRZEPATIDEApproval Type
New Drug (NDA)
FDA Application
NDA215866FDA Approved
5/13/2022
On Market Since
5/13/2022
Pharmacological Classes
Price Statistics
The NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has been published 202 times since Nov 23, 2022, and over the history we have for it it has risen 15.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $538.5252 per ML |
|---|---|
| All-time high | $538.5770 (May 13, 2026) |
| All-time low | $468.2471 (Nov 23, 2022) |
| 52-week high | $538.5770 |
| 52-week low | $522.8024 |
| Median price | $515.5590 |
| Average price | $513.9438 |
| Largest weekly change | +5.0% (Jan 11, 2023) |
| Weeks tracked | 202 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tirzepatide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOUNJARO 12.5 MG/0.5 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for MOUNJARO 12.5 MG/0.5 ML PEN, manufactured by Eli Lilly and Company, is $538.5252 per ML (NDC 00002146080), effective Sep 30, 2026.
How has the price of MOUNJARO 12.5 MG/0.5 ML PEN changed over time?
Over the history we have for it, the NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has risen 15.0%. It has been tracked across 202 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for MOUNJARO 12.5 MG/0.5 ML PEN?
Since Nov 23, 2022, the NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has ranged from a low of $468.2471 (Nov 23, 2022) to a high of $538.5770 (May 13, 2026), with a median of $515.5590 per ML.
Are there cheaper alternatives to MOUNJARO 12.5 MG/0.5 ML PEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZEPBOUND 12.5 MG/0.5 ML PEN, is $525.8487 per ML — about 2% below MOUNJARO 12.5 MG/0.5 ML PEN.
Who manufactures MOUNJARO 12.5 MG/0.5 ML PEN?
MOUNJARO 12.5 MG/0.5 ML PEN (NDC 00002146080) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.